Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|11/11/15||IRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting|
|Glaucoma System to Make First Ever AAO Appearance at 119th Annual Meeting
MOUNTAIN VIEW, Calif., Nov. 11, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced its attendance at the 119th annual American Academy of Ophthalmology (AAO) Meeting. The Company will feature its latest product, the Cyclo G6™ laser system equipped with MicroPulse tissue sparing glaucoma technology for the treatment of a range of glaucoma disease states. This will be the first time the Cyclo G6 will b... |
|11/05/15||IRIDEX Reports 2015 Third Quarter, Nine-Month Results|
|MOUNTAIN VIEW, Calif., Nov. 5, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended October 3, 2015.
Revenues were $9.8 million in the third quarter of 2015 compared to $10.1 million in the 2014 third quarter and $9.0 million in the second quarter of 2015. For the first nine months of 2015, revenues were $29.6 million compared to $31.0 million in the prior year period.
Gross margin for the 2015 third q... |
|10/29/15||IRIDEX Announces Third Quarter 2015 Conference Call and Release Date|
|MOUNTAIN VIEW, Calif., Oct. 29, 2015 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2015 financial results after the market closes on Thursday, November 5, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, November 5, 2015 to discuss the results of the quarter and other business developments.
Interested parties may access the live confe... |
|09/08/15||IRIDEX Broadens Global Glaucoma Outreach With Novel Eye Pressure Diagnostic Device|
|Icare's Tonometer for Monitoring Intra-Ocular Pressure Adds to Recurring Revenue Stream
MOUNTAIN VIEW, Calif., Sept. 8, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of commercial products for the global glaucoma market. The new device comes to IRIDEX through a distribution agreement with Icare Finland Plc, a subsidiary of the Revenio Group Corporation, the creator ... |
|Primary IR Contact|
President and CEO
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.